Prevalence and direct costs of vestibular disease in France – matched case-control study Results from the 2022 and 2023 French health data system
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Importance : Vestibular dysfunction causes vertigo, dizziness, and imbalance, impairing daily life and leading to substantial healthcare use. Precise prevalence and economic impact remain unclear. Objective : To estimate the one-year prevalence and direct healthcare costs of vestibular disorders in France. Design : A matched case-control study using the French national health data system covering over 67 million records in 2022. Setting : Nationwide health insurance data including all public and private healthcare interactions. Population : Adults aged ≥18 years diagnosed or treated for vestibular disease, matched 1:1 with controls by age, sex, comorbidities, region, and deprivation. Exposure : Vestibular disorder diagnosis or treatment in 2022. Outcome : Direct healthcare expenditures in 2022 and 2023. Results : Vestibular disorders affected 2.5% of adults (1,279,966 cases). Cases incurred mean costs of €4,233 versus €3,719 in controls in 2023, with an excess of €657 million nationally. Conclusions and Relevance : Vestibular disorders are common and associated with significant excess healthcare costs. Standardizing diagnostic and therapeutic pathways may reduce expenditures and improve care quality.
